Drug
Isis 14803
Isis 14803: highest development phase Phase 1/2, developed by Ionis Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ISIS 14803, peginterferon alfa, ribavirin NCT00062816 | Phase 1/2 | Hepatitis C, Chronic |
Latest
No recent events.
Follow Isis 14803 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.